A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Castration-Resistant Prostatic Cancer · Metastasis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 360 (planned)
- Started
- Jul 3, 2025
- Main results expected
- Oct 1, 2031
- Fully finished
- Oct 1, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Measured over: Up to approximately 21 days
Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)
Measured over: Up to approximately 54 months
Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AE
Measured over: Up to approximately 24 months
Efficacy Phase: Prostate-Specific Antigen (PSA) response rate
Measured over: Up to approximately 54 months
Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Measured over: Up to approximately 21 days
Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms Only
Measured over: Up to approximately 21 days
Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms Only
Measured over: Up to approximately 21 days
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06863272 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC